• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

cis-Platinum: subcellular distribution and binding to cytosolic ligands.

作者信息

Sharma R P, Edwards I R

出版信息

Biochem Pharmacol. 1983 Sep 15;32(18):2665-9. doi: 10.1016/0006-2952(83)90073-4.

DOI:10.1016/0006-2952(83)90073-4
PMID:6313005
Abstract

In the present experiments the tissue uptake and subcellular distribution of Pt were measured in the liver and kidney of rats injected intraperitonially with 5 mg cis-diamminedichloroplatinum (cis-DPP)/kg. The binding of Pt to cytosolic ligands was also investigated. In both the liver and kidney Pt concentration was maximal within 24 hr following cis-DDP injection. Thereafter the clearance was bimodal with a rapid phase of about 48 hr (with 60-70% clearance) followed by a slow incomplete phase. In the kidney relatively high concentrations of Pt were measured in the microsomal, lysosomal and mitochondrial fractions. But in the liver the higher levels were found in the microsomal and nuclear fractions. On average 62% (kidney) and 89% (liver) of the cellular Pt were localized in the cytosol. At 24 hr following cis-DDP injection, about 52% of cytosolic Pt was present as low molecular weight species (molecular weight less than 1000) and the remainder as protein-bound. About 25% was bound to a metallothionein-like protein in the liver as well as the kidneys. It is suggested that the high localization of cellular Pt in the cytosol and the presence of a high proportion as non-protein bound species may be important factors in relation to the therapeutic as well as the toxic effects of cis-DDP.

摘要

相似文献

1
cis-Platinum: subcellular distribution and binding to cytosolic ligands.
Biochem Pharmacol. 1983 Sep 15;32(18):2665-9. doi: 10.1016/0006-2952(83)90073-4.
2
Interactions of cis-platinum with cellular zinc and copper in rat liver and kidney tissues.顺铂与大鼠肝脏和肾脏组织中细胞锌和铜的相互作用。
Pharmacol Res Commun. 1985 Feb;17(2):197-206. doi: 10.1016/0031-6989(85)90065-7.
3
The interactions of cis-diamminedichloroplatinum with metallothionein and glutathione in rat liver and kidney.顺二氯二氨合铂与大鼠肝脏和肾脏中金属硫蛋白及谷胱甘肽的相互作用。
Toxicology. 1990 Nov;64(2):113-27. doi: 10.1016/0300-483x(90)90129-5.
4
Cisplatinum: effect of zinc acetate pretreatment on cellular uptake and interactions with cytosolic ligands.
Toxicology. 1984 Jul;32(1):75-84. doi: 10.1016/0300-483x(84)90036-2.
5
Interaction of platinum with metallothionein-like ligands in the rat kidney after administration of cis-dichlorodiammine platinum II.给予顺二氯二氨铂(II)后大鼠肾脏中铂与类金属硫蛋白配体的相互作用。
Chem Biol Interact. 1984 Apr;49(1-2):165-76. doi: 10.1016/0009-2797(84)90059-0.
6
Interaction of cis- and trans-diamminedichloroplatinum with metallothionein in vivo.顺式和反式二氯二氨铂在体内与金属硫蛋白的相互作用。
J Inorg Biochem. 1995 Apr;58(1):1-8. doi: 10.1016/0162-0134(94)00030-e.
7
In vivo and in vitro binding of platinum to metallothionein.铂在体内和体外与金属硫蛋白的结合
Arch Biochem Biophys. 1984 Feb 15;229(1):246-52. doi: 10.1016/0003-9861(84)90150-4.
8
Distribution of Pt in the urine and kidney of the cisplatin treated rat.顺铂处理大鼠尿液和肾脏中铂的分布。
Toxicology. 1986 Feb;38(2):219-26. doi: 10.1016/0300-483x(86)90123-x.
9
Time course of the binding of platinum to subfractions of the kidney cytosol in the cisplatin-treated rat.
Res Commun Chem Pathol Pharmacol. 1986 Apr;52(1):51-8.
10
Quantitative subcellular distribution of platinum in rat tissues following i.v. bolus and i.v. infusion of cisplatin.静脉推注和顺铂静脉输注后大鼠组织中铂的定量亚细胞分布。
Cancer Chemother Pharmacol. 1990;26(3):188-92. doi: 10.1007/BF02897197.

引用本文的文献

1
NanoSIMS combined with fluorescence microscopy as a tool for subcellular imaging of isotopically labeled platinum-based anticancer drugs.纳米二次离子质谱联用荧光显微镜作为对同位素标记的铂类抗癌药物进行亚细胞成像的工具。
Chem Sci. 2014 Jun 6;5(8):3135-3143. doi: 10.1039/c3sc53426j. eCollection 2014 Jun 30.
2
Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia.生长激素促分泌素 hexarelin 和 JMV2894 可保护顺铂诱导的恶病质大鼠模型中的骨骼肌免受线粒体损伤。
Sci Rep. 2017 Oct 12;7(1):13017. doi: 10.1038/s41598-017-13504-y.
3
Mitochondrial ClpP activity is required for cisplatin resistance in human cells.
线粒体ClpP活性是人类细胞顺铂耐药性所必需的。
Biochim Biophys Acta. 2016 Feb;1862(2):252-64. doi: 10.1016/j.bbadis.2015.12.005. Epub 2015 Dec 7.
4
Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs.评估荧光团连接的铂配合物以监测顺铂类似物的去向。
J Biol Inorg Chem. 2015 Oct;20(7):1081-95. doi: 10.1007/s00775-015-1290-2. Epub 2015 Sep 1.
5
Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics.OATP1B 型转运体功能的调节会改变铂类化疗药物的细胞摄取和处置。
Mol Cancer Ther. 2013 Aug;12(8):1537-44. doi: 10.1158/1535-7163.MCT-12-0926. Epub 2013 Jun 11.
6
Preferential energy- and potential-dependent accumulation of cisplatin-gutathione complexes in human cancer cell lines (GLC4 and K562): A likely role of mitochondria.
J Bioenerg Biomembr. 2006 Feb;38(1):11-21. doi: 10.1007/s10863-006-9001-x. Epub 2006 May 27.
7
Folate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cells in vitro for neutron capture therapy.叶酸受体介导的亲脂性硼剂脂质体体外递送用于肿瘤细胞的中子俘获治疗。
Pharm Res. 2002 Oct;19(10):1502-8. doi: 10.1023/a:1020408716807.
8
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells.金属硫蛋白介导的人卵巢癌细胞顺铂耐药性
Cancer Chemother Pharmacol. 1987;19(2):149-54. doi: 10.1007/BF00254568.
9
The effect of cisplatin on renal ATPase activity in vivo and in vitro.顺铂对体内和体外肾ATP酶活性的影响。
Cancer Chemother Pharmacol. 1985;15(2):93-6. doi: 10.1007/BF00257515.
10
Quantitative subcellular distribution of platinum in rat tissues following i.v. bolus and i.v. infusion of cisplatin.静脉推注和顺铂静脉输注后大鼠组织中铂的定量亚细胞分布。
Cancer Chemother Pharmacol. 1990;26(3):188-92. doi: 10.1007/BF02897197.